Is Aldeyra Therapeutics, Inc. (ALDX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.3% / 30% | 35.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 5.3% / 33% | 35.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 14.6% / 33% | 96.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.3% / 33% | 35.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 14.6% / 33% | 96.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -58.7% | |
| Return on Assets (ROA) | -25.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $16M |
| Debt-to-Equity | 35.1 |
| Current Ratio | 2.6 |
| Total Assets | $72M |
Price & Trading
| Last Close | $1.84 |
| 50-Day MA | $4.52 |
| 200-Day MA | $4.84 |
| Avg Volume | 2.5M |
| Beta | 1.0 |
|
52-Week Range
$1.07
| |
About Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aldeyra Therapeutics, Inc. (ALDX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aldeyra Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aldeyra Therapeutics, Inc.'s debt ratio?
Aldeyra Therapeutics, Inc.'s debt ratio is 5.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.6%.
What are Aldeyra Therapeutics, Inc.'s key financial metrics?
Aldeyra Therapeutics, Inc. has a market capitalization of $107M. Return on equity stands at -58.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.